NTX-250 / Nutcracker Therap - LARVOL DELTA

NTX250: A Modular mRNA-Based Immunotherapy Platform for HPV-Associated Cancers with Broad Applicability. (PubMed, bioRxiv) - "Moreover, this modular mRNA nanoparticle approach combining tumor-specific antigens and immunomodulators is adaptable beyond HPV, with potential applications targeting neoepitopes or other tumor-associated antigens, thus offering a versatile platform for immunotherapy across a broad range of indications. These findings highlight the potential of this strategy as a broadly applicable, non-surgical immunotherapeutic capable of inducing robust and specific anti-tumor responses."

Journal • Cervical Cancer • Gynecology • Human Papillomavirus Infection • Infectious Disease • Oncology • IL12A

Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting (Businesswire) - "Nutcracker Therapeutics...recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data for the company’s mRNA drug candidate for prostate cancer, NTX-470; and the other highlighting data on the immunomodulatory cytokine, LIGHT....Data showed NTX-470 successfully engaged CD3 T cells, while retaining low bystander activity and reduced off-tumor binding. Another set of data detailed the design of LIGHT, an immunomodulatory cytokine that is a component of lead drug candidate NTX-250."

Preclinical • Prostate Cancer

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024 (Businesswire) - "Nutcracker Therapeutics, Inc...announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The first presentation entails LIGHT, an immunomodulatory cytokine that is one of the components of NTX-250, the company’s lead candidate for cervical intraepithelial neoplasia. The second presentation is on preclinical data for Nutcracker’s mRNA drug candidate for prostate cancer, NTX-470."

Preclinical • Cervical Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Solid Tumor

Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting (Businesswire) - "Nutcracker Therapeutics, Inc...presented preclinical data for two of its therapeutic candidates: its latest therapeutic candidate, NTX-471, which targets CD47; and the company’s lead mRNA candidate targeting human papillomavirus (HPV)-driven tumors, NTX-250...Key highlights of the data include...Administering mice with formulated mRNA molecules encoding the tetravalent, octavalent, and bispecific SIRPa fully eradicated established subcutaneous tumors, and resulted in robust protein expression (~10-100ug/ml) with high purity/homogeneity similar to, or better than, DNA-expressed proteins...Two doses of mNTX-250 treatment eradicated well-established HPV16-transformed tumors, and improved overall survival in mice. The treated animals also generated significant numbers of HPV-16 E7 antigen-specific T cells....Mice treated with NTX-010 generated fewer HPV16 antigen-specific T cells. When rechallenged, 6 out of 11 NTX-010-treated mice showed tumor growth."

Preclinical • Oncology • Solid Tumor

mNTX-250, a novel multimodal HPV-16 mRNA-based therapeutic, induces potent anti-tumor responses and establishes HPV-16 specific immune memory (SITC 2023) - "Methods In this study, we studied in vivo efficacy, pharmacodynamics and the establishment of antigen-specific immune memory against HPV-16 antigens of mNTX-250 (a murine surrogate of NTX-250), in comparison with NTX-010 (consisting of noncoding mRNA, murine IL-12 and murine LIGHT) in C3. Conclusions mNTX-250 demonstrated significant antitumor efficacy in the C3. 43 tumor model and generated HPV-16 antigen specific immune memory that was sufficient to protect the host from re-challenge with another HPV-16 driven tumor."

Cervical Cancer • Oncology • Solid Tumor • IL12A

Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023 (Businesswire) - "Nutcracker Therapeutics, Inc...announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4....Nutcracker’s presentation on NTX-250 will describe how its three RNA-encoded protein components (HPV E6/E7, IL-12, and LIGHT) work together to drive enhanced immune responses and tumor clearance in murine models of HPV-driven tumors, while also providing immunogenic memory. The presentation on NTX-471 will describe unique mRNA compositions that can selectively target CD47 on cancerous cells over those on red blood cells, potentially alleviating the anemic side effects seen with anti-CD47 drugs currently under development."

Preclinical • Oncology • Solid Tumor

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting (Businesswire) - "Nutcracker Therapeutics...presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting....Complete tumor regression and long-term, recurrence-free survival in all 10 tumor-challenged mice intratumorally administered with NTX-250. No tumor-free mice in the negative control group or in mice treated intramuscularly with NTX-250....NTX-250 is expected to enter Phase I clinical trials by early 2024."

New P1 trial • Preclinical • Oncology • Solid Tumor

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting (Businesswire) - "Nutcracker’s poster presentation #5163 outlined how NTX-250 stimulates an immune response to clear HPV-driven tumors in murine models via the synergistic interactions between its three RNA-encoded protein components — the HPV16 E6 and E7 antigens, and immunomodulators IL-12 and LIGHT — which are delivered locally into the tumor as a single mRNA drug product...Notable takeaways from the data include: Complete tumor regression and long-term, recurrence-free survival in all 10 tumor-challenged mice intratumorally administered with NTX-250. No tumor-free mice in the negative control group or in mice treated intramuscularly with NTX-250. Intratumoral injection of NTX-250 resulted in immune cell infiltration and the secretion of proinflammatory Th1/M1 associated cytokines, which aid in turning 'cold' tumors 'hot'."

Preclinical • Oncology

NTX-0250, a multimodal mRNA-based immunotherapy, eradicates large established tumors in a stringent mouse model of HPV16-driven cancer (SITC 2022) - "Conclusions Here we report for the first time robust pre-clinical efficacy of a multimodal, mRNA-based therapeutic combining antigen- and immunomodulator-encoding mRNAs in a novel nanoparticle formulation. NTX-0250 treatment resulted in complete regression of large established murine tumors and robust induction of HPV-specific T cell responses in non-human primates."

Preclinical • Cervical Cancer • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • CD4 • CD8 • IFNG

Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022 (Businesswire) - "Nutcracker Therapeutics...presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induces an immune response in non-human primates specific to human papillomavirus (HPV)....A Phase I clinical trial for NTX-250 is planned for 2023, pending the clearance of an Investigational New Drug application by the Food and Drug Administration."

New P1 trial • Preclinical • Oncology • Solid Tumor

Nutcracker Therapeutics to Present Data for Lead Candidate at 2022 SITC Annual Meeting (Businesswire) - "Nutcracker Therapeutics, Inc...announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers. The company will present this data at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), being held in Boston, MA, from November 8-12, 2022....The poster presentation will showcase data that demonstrates that NTX-0250, a multimodal, mRNA-based therapeutic, is capable of inducing the complete regression of large murine tumors."

Preclinical • Oncology • Solid Tumor